Regulated information

2017 sales: €352.2 million 7.6% like-for-like growth in essentials products

The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%.  

Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT

Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. 

Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates.

Reference products up 6.1% like-for-like in H1 net income group share up 6.5% to €14.4 million

At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

Résultats du scrutin de l'Assemblée générale du 30 mai 2017 (french)

Assemblée générale mixte du 30 mai 2017

Présentation à l'Assemblée générale du 30 mai 2017 (french)

Assemblée Générale Mixte - 30 mai 2017 15h30

Formulaire de vote (French)

ASSEMBLEE GENERALE MIXTE du 30 MAI 2017 à 15h30

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le mardi 30 mai 2017 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2016 (french version)

The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.

Q1 2017 sales stable at €86.1 million

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

All key financial indicators up in 2016

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

September 2016 year-to-date sales: €257.5 million a 4.8% organic growth

Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. 

Vetoquinol launches its employer brand

The veterinary pharmaceutical company Vetoquinol launches its employer brand. For 83 years, Vetoquinol has been building its future, drawing on relationships of trust with its partners, the development of every employee, and its long-held belief of continuous improvement. Following on from its corporate brand, the company is now positioning itself as a high-quality employer.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 (french)

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2016 

Dynamic first half 2016

2016 Half year Financial Report

Résultats du scrutin de l'Assemblée générale du 24 mai 2016 (french)

Assemblée générale mixte du 24 mai 2016

ASSEMBLEE GENERALE 2016 (french)

Assemblée Générale 2016 (french)

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The Registration document of Vetoquinol relative to fiscal year 2015, including the Annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 26, 2016.

Formulaire de vote (French)

ASSEMBLEE GENERALE MIXTE du 24 MAI 2016 à 14h 

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le mardi 24 mai 2016 à 14h00, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants : 

Q1 sales: €85.8M

Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%.

2015 results sales of reference products up 9.4% ebit up 10.3%

At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.

2015 sales up 8.7% to €342.6 million

The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound.

Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon

Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan.

September 2015 year-to-date sales up 8.7% to €251.8 million

Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%.

VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs

Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs.

First half 2015 sales €167.2m, up 11.9%

The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.

Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french)

Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites
Internet de :
- Vétoquinol (www.vetoquinol.com)
- l’AMF (www.amf-france.org)

Vétoquinol is eligible for new PEA-PME funds

Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree
n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-
1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

Résultat du scrutin de l'Assemblée générale du 20 mai 2015 (french)

Résultat du scrutin de l'Assemblée générale du 20 mai 2015

Assemblée Générale Mixte du 20 mai 2015 : exercice 2014

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version)

The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015.

Convocation à l'Assemblée générale mixte du 20 mai 2015

Formulaire Assemblée Générale du 20 mai 2015

Q1 2015 sales show solid growth at €81.3 million (up +11.0%)

Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014.

Reference products up +13.2%. net income up +9.3%

Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements.

Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration

Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products.

2014 sales up 5.2% to €315.3 million

The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014.

Information relative au code de gouvernance

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF.

Information relative au Code de Gouvernance (french)

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les
administrateurs ont adopté le code de gouvernance Middlenext. Depuis
2008, Vétoquinol se référait au code AFEP-MEDEF.

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

Solid growth in Q2 2014: 8.8% first half net income up 4.2%

At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014.

Résultat du scrutin de l'Assemblée générale du 13 mai 2014

Assemblée Générale Mixte du 13 mai 2014 : exercice 2013

Convocation à l'Assemblée générale mixte du 13 mai 2014

Formulaire Assemblée Générale du 13 mai 2014

Assemblée générale mixte du 13 mai 2014 - exposé des motifs

Résultats des cinq derniers exercices

Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business

Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction.

Reference products up 2.2% in Q1 2014

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

Vétoquinol is eligible for new PEA-PME funds

Lure (France), April 2, 2014 – Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME

2013 growth driven by reference products

Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements.

Vétoquinol to acquire the animal health business of Bioniche Life Sciences Inc.

LURE, FRANCE and BELLEVILLE, ONTARIO, CANADA, February 27, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche’s Animal Health business for the cash purchase price of CAD$61 million.

7.8% organic growth in Q4 2013

The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012.

Jean-Yves RAVINET appointed Group Chief Operating Officer

Lure (France), January 7, 2014 – The Vétoquinol Group announces the appointment of Jean-Yves Ravinet as Group Chief Operating Officer.

Vétoquinol continues to launch reference products

Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States.

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

The reference products demonstrate solid growth

Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013.

Q2 2013 sales

Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like.

Procès-verbal des délibérations de l'assemblée générale mixte du 22 mai 2013

Résultats du scrutin de l'Assemblée générale du 22 mai 2013 (french)

Résultats du scrutin  de l'Assemblée générale du 22 mai 2013

Assemblée Générale Mixte du 22 mai 2013
: Résultats annuels 2012

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version)

The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013.

Q1 2013 sales

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

Convocation à l'Assemblée générale mixte du 22 mai 2013

Formulaire Assemblée Générale du 22 mai 2013

Assemblée générale mixte du 22 mai 2013 - exposé des motifs

Résultats des cinq derniers exercices

2012, return to growth

Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements.

2012 sales up 5.0%

Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%.

Forcyl® - a booming brand

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

Sales momentum continues in Q3

Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year.

Vétoquinol purchases ORSCO laboratoire vétérinaire

Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire.

Vétoquinol returns to growth

Lure (France), 29 August 2012 – At its 29 August 2012 meeting, the Vétoquinol S.A. board of directors reviewed the Group results and approved the financial statements for the first six months of 2012.

Solid first half 2012 Sales

First half 2012 sales reached €146.8 million, up 5.1% over first half 2011.

Quorum 2012

Assemblée générale ordinaire -
24 mai 2012

Résultats du scrutin de l'Assemblée générale du 24 mai 2012 (french)

Résultats du scrutin

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2011 (french version)

The registration document of Vétoquinol relative to fiscal year 2011, including the annual financial report relative to fiscal year 2011, was registered with the Autorité des marchés financiers (“the AMF”) on April 20th, 2012.

Strong Revenue growth in the first quarter of 2012

Vétoquinol achieved Q1 2012 sales of €77.0 million, up 15.9% compared to Q1 2011.

Formulaire droit de vote (french)

Formulaire de vote pour l'Assemblée Générale du 24 mai 2012

CONVOCATION : assemblée d'actionnaires et de porteurs de parts (french)

Avis de réunion valant avis de convocation.
<br>
Mesdames et Messieurs les actionnaires sont convoqués le jeudi 24 mai 2012 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne - 70200 Lure, en
Assemblée générale ordinaire, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

2011 annual earnings

Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements.

Flevox® the new parasiticide for dogs and cats

Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets.

2011, a year of transition

Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis.

Q3 2011 Sales

Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Vétoquinol continues to develop its product ranges and enters the brazilian market

Lure (France), August 30, 2011 – The Vetoquinol Board Meeting of August 29, 2011 reviewed the Group’s business and approved the financial statements for the first half 2011.

Procès-verbal des délibérations de l'assemblée générale mixte du 20 mai 2011

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

Arrêté de la feuille de présence (french)

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

VÉTOQUINOL enters the brazilian Market

Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil.

Résultat du scrutin de l'Assemblée générale du 20 mai 2011

Présentation à l'Assemblée générale du 20 mai 2011

Formulaire droit de vote (french)

Formulaire de vote pour l'Assemblée Générale du 20 mai 2011

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2010 (french version)

The registration document of Vétoquinol relative to fiscal year 2010, including the annual financial report relative to fiscal year 2010, was registered with the Autorité des marchés financiers (“the AMF”) on April 18th, 2011.